Font Size: a A A

Study On The Relationship Between Expression Of PD-L1 And The Efficacy Of Neoadjuvant Therapy For Rectal Cancer

Posted on:2020-08-20Degree:MasterType:Thesis
Country:ChinaCandidate:X W WangFull Text:PDF
GTID:2404330590965248Subject:Surgery
Abstract/Summary:PDF Full Text Request
Objective: The expression of PD-L1 before neoadjuvant therapy for rectal cancer,and to explore the correlation between its expression and neoadjuvant therapy and clinical and pathological features of rectal cancer.Methods:1.A retrospective selection of patients from the second surgical department of the Fourth Hospital of Hebei Medical University from November 2015 to November 2018 was diagnosed as rectal cancer by biopsy.The clinical evaluation was local metaphase and advanced rectal cancer.After neoadjuvant therapy Forty-three patients underwent TME surgery for 6-8 weeks.2.Tumor tissue wax blocks were collected from the pathology department before neoadjuvant treatment,tissue microarrays were prepared,and immunohistochemical detection of PD-L1 molecules was performed.3.Data analysis was performed using SPSS21,and the statistical method was tested according to the use criteria,Pearson chi-square test,chi-square test for continuity correction,and Fisher’s test.Logistic regression was used for the analysis of multiple factors,with P<0.05 being statistically significant.Results: Among the 43 patients enrolled,5 cases(11.6%)were positive for PD-L1 expression.Among them,the clinical data showed that the gender,age,distance from the anus,clinical evaluation of lymph node invasion,clinical T stage cT3/cT4 and PD-L1 expression were not statistically different.There was no significant difference in the expression of PD-L1 between the invasive or non-invasive pathological data,the presence or absence of vascular tumor,the grade of tumor regression,the pathological T stage and the neoadjuvant treatment.There was a statistical difference in the presence or absence of lymph node metastasis and PD-L1 expression in the pathological data(P=0.039<0.05).Conclusions:1.There was no significant correlation between the expression of PD-L1 and neoadjuvant therapy before neoadjuvant therapy with neoadjuvant therapy with long-term radiotherapy and two Xelox regimens.2.In the cases of local matephase and advanced rectal cancer,the expression of PD-L1 before neoadjuvant therapy was positively correlated with the presence or absence of lymph node metastasis.
Keywords/Search Tags:PD-L1, Neoadjuvant therapy, Rectal cancer, Tumor regression grade, Immune microenvironment
PDF Full Text Request
Related items
Relationship Between Tumor Regression Grade And Long-Term Prognosis After Preoperative Neoadjuvant Therapy For Locally Advanced Rectal Cancer
Clinical Research And Response Prediction Biomarkers Associated With Neoadjuvant Chemoradiotherapy In Locally Advanced Rectal Cancer
1.The Prognostic Significance Of The Treatment Response Of Regional Lymph Nodes And The Refinement Of Current TNM Staging System In Locally Advanced Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy 2.The Safety And Efficacy Of Radical Surgery Fo
A Study On The Correlation Between Lymph Nodes And Tumor Regression Grade After Neoadjuvant Chemoradiotherapy In Rectal Cancer
Multivariate Analysis Of Clinicopathologic Factors And Prognostic Significance Of Tumor Regression After Neoadjuvant Therapy In Locally Advanced Rectal Cancer
Analysis Of Influencing Factors And Prognostic Significance Of Tumor Regression Grade In Patients With Rectal Carcinoma Treated With Neoadjuvant Therapy
Correlation Between Tumor Microenvironment-related Factors And The Efficacy And Prognosis Of Neoadjuvant Therapy For Rectal Cancer
Evaluation Of The Primary Tumor And Immune Microenvironment In Rectal Cancer After Neoadjuvant Chemoradiotherapy
Study On The Relationship Between Tumor Regression Grade And Changes Of T Lymphocytes And Their Subsets And Toxicity In Patients With Locally Advanced Middle And Low Rectal Cancer After Neoadjuvant Chemoradiotherapy
10 Prognostic Effect Of Different Tumor Regression Grade Systems In Breast Cancer Patients Who Received Neoadjuvant Therapy